Price movement over the last 24 hours
Adaptive Biotechnologies Corp vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.22 (market cap $3.33B), while State Street Real Estate Select Sector SPDR ETF trades at $44.23. Which is the better fit depends on your goals.
| ADPT | XLRE | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $45.36 |
52-Week Low | $10.24 | $40.01 |
Enterprise Value | $3.19B | — |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
XLRE trades at $44.29, down 0.9% on the day, with technical indicators showing a neutral to bearish bias. The ETF maintains a low 0.08% expense ratio and focuses exclusively on U.S. real estate investment trusts. Recent news highlights XLRE's cost advantage over global real estate ETFs and discusses the REIT sector's resilience amid interest rate volatility.
The outlook for XLRE hinges on U.S. real estate fundamentals and interest rate trends. Opportunities include potential sector recovery and durable dividends, but risks remain from rising Treasury yields and economic uncertainty. Wall Street sentiment is mixed, with technicals suggesting near-term consolidation around key support at $44.
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →